Navigation Links
PharmaMar Commences Clinical Trial in U.S. with New Antitumor Product, PM060184
Date:2/7/2011

MADRID, Feb. 7, 2011 /PRNewswire/ -- PharmaMar SA (Grupo Zeltia, ZEL.MC) has announced the commencement of a Phase I clinical trial with PM060184 for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced compound which has shown strong in vitro and in vivo antitumor activity and a favorable safety profile in preclinical toxicology studies. PM060184 is PharmaMar's sixth compound in clinical development.

The trials will be performed in hospitals in the U.S., and also in France and Spain. The primary endpoints of this Phase I trial are to identify the dose limiting toxicity (DLT), the maximum tolerated dose (MTD) and the recommended dose (RD) of PM060184.

Additionally, the drug's pharmacokinetic profile will be defined and a preliminary evaluation of its antitumor activity in patients will be performed.

About PharmaMar

PharmaMar is Grupo Zeltia's biotechnology subsidiary; it is a world leader in discovering, developing and selling marine-based drugs to treat cancer. Yondelis® is Spain's first antitumor drug. Yondelis® is currently approved for STS in 33 countries outside the EEA, and in 10 of those countries for platinum-sensitive ROC as well (including Brazil and Canada). Yondelis® is approved for STS and platinum-sensitive ROC in all 30 countries of the EEA; in Switzerland it is approved for STS. Phase II clinical trials with Yondelis® are also under way on prostate, breast, lung and pediatric cancers. PharmaMar has five other compounds in clinical development: Aplidin®, Irvalec®, Zalypsis®, PM01183 and PM060184. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D program.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following
'/>"/>

SOURCE PharmaMar
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention
2. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
3. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
4. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
5. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
6. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
7. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
8. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
9. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
10. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
11. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Pa. , July 31, 2015 ... fully integrated specialty pharmaceutical company focused on developing, ... the closing of its previously announced underwritten public ... at a public offering price of $11.25 per ... offering included 1,000,000 shares issued upon the exercise ...
(Date:7/31/2015)... and SAN DIEGO , ... its parent company Eisai Co., Ltd. (Headquarters: ... , "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: ... Helen Torley , "NASDAQ: HALO") have signed a ... name: Halaven ® , "eribulin") in combination with Halozyme,s ...
(Date:7/31/2015)... According to a new market ... Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold Calipers, Air ... & Forecast to 2019", published by MarketsandMarkets, the global ... 2014 and is estimated to grow to $1,425.7 Million ... 2014 to 2019. Browse 41 market ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
... June 16, 2011 Reportlinker.com announces that a ... catalogue: UK CT Systems – ... http://www.reportlinker.com/p0555197/UK-CT-Systems-–-Market-Trend-Till-2016.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging Short Description ... data on the CT systems in UK. It ...
... Inc., a leading provider of software solutions to ... today announced that a number of pharmaceutical industry ... participate in the creation of a set of ... performance data. Each of the initial sponsors will ...
Cached Medicine Technology:Reportlinker Adds UK CT Systems - Market Trend Till 2016 2DecisionView to Create Clinical Trial Enrollment Benchmarks 2DecisionView to Create Clinical Trial Enrollment Benchmarks 3
(Date:8/1/2015)... ... August 01, 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s Royal River ... honor by the National Retail Federation, the largest retail trade association in the world, ... Maine business owners to be named as such. According to the NRF’s website, Retail ...
(Date:8/1/2015)... , ... August 01, 2015 , ... BeverlyD, owner and ... March4thforWellBeing foundation, making hers the very first small business donation to kick off the ... for over thirty years. Her legacy includes a complete line of raw, organic hair ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot and warm-season turfgrasses, ... of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, ... of this new type of sod, Super-Sod is giving away red Adirondack chairs with ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted by Becker’s Healthcare ... health analytics , Jvion continues to disrupt the predictive analytic and big data ... patient and population level illness to drive prevention and better health outcomes. Most ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... at its new True North Conference Center. The medical community, social workers, law ... community may be more aligned in the effort to better understand and combat ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3
... By Jenifer Goodwin HealthDay Reporter , ... that biomarkers in the blood may help diagnose Alzheimer,s ... better treatments. While there are currently no treatments ... disease, the hope is that being able to diagnose ...
... researchers from around the world will be in Milwaukee, ... gaining insights into the brain,s inner workings to better ... and how the brain is altered by neurological diseases ... 350 scientists will attend the Second International Conference on ...
... 13, 2010) - A protein crucial for the immune ... of a devastating form of childhood leukemia called T-cell acute ... the leukemic cells, the study shows, opening a potential avenue ... Led by Iannis Aifantis, PhD, associate professor of ...
... musty odors, along with visual evidence of blue-green algae, ... that harmful cyanotoxins are present in lakes or reservoirs. ... in Midwest lakes, taste-and-odor compounds were found almost every ... a warning that harmful toxins are present. "It ...
... paralysed found that their condition improved after they received a ... in the September issue of the European Journal of ... University in Cairo, Egypt, studied 60 patients with ischaemic stroke ... - who had been left with mild to moderate muscle ...
... Union, its incidence increased by almost 20%, from 2.1 million new ... issue [1] of the European Journal of Cancer (the ... prevention, published today (Monday 13 September). ... number of areas, says a paper by Dr. Jos M. Martin-Moreno ...
Cached Medicine News:Health News:Biomarkers May Aid in Early Diagnosis of Alzheimer's 2Health News:Biomarkers May Aid in Early Diagnosis of Alzheimer's 3Health News:Leading brain scientists meet in Milwaukee to examine how to uncover the brain's secrets 2Health News:Leading brain scientists meet in Milwaukee to examine how to uncover the brain's secrets 3Health News:NYU Langone scientists find key pathway implicated in progression of childhood cancer 2Health News:If the water looks and smells bad, it may be toxic 2Health News:Brain stimulation can help partially paralyzed stroke patients regain use of their muscles 2Health News:Cancer deaths fall, but prevention still lags behind 2Health News:Cancer deaths fall, but prevention still lags behind 3Health News:Cancer deaths fall, but prevention still lags behind 4Health News:Cancer deaths fall, but prevention still lags behind 5
The Lifestream Cholesterol Monitor provides you with a comprehensive tool to help you monitor your cholesterol as part of your wellness program. At a later date, you can purchase the other components...
... The HemoCue Glucose 201+ is the latest ... as the earlier versions, the new system combines ... with a quick turn around time and ease ... stores results and QC results, together with date ...
... using patented, innovative technology, measures a complete ... only 5 minutes from a simple fingerstick. ... get immediate liver function results. The scope ... only advantage to healthcare providers. The physician, ...
CardioChek™ PA Portable Whole Blood Test System...
Medicine Products: